Abstract
The use of platelets for transfusion has increased dramatically over the past 20 years since the use of chemotherapy has become a routine treatment for patients with cancer. Within the most recent decade, the application of bone marrow transplantation to many malignancies not previously treated with this modality, and the identification and production of large quantities of human cytokines have resulted in larger numbers of patients receiving higher doses of chemotherapy. Although the cytokines currently used are potent stimulants of granulocytopoiesis and erythropoiesis, none yet discovered has been shown to stimulate production of platelets. A recent study that evaluated patterns in blood transfusion in the United States between 1982 and 1988 found that the number of red blood cell units transfused has remained the same. Over the same interval, there was a 50% increase in the number of units of platelets transfused. Indeed, the use of platelets obtained from a single donor by apheresis has grown even more rapidly, increasing from 16.8% of all platelet transfusions in 1982 to 24.6% in 1987 [1]. It seems likely that the usage of platelets will continue to increase.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Surgenor DMN, Wallace EL, Hao SHS, Chapman RH. Collection and transfusion of blood in the United States, 1982–1988. N Engl J Med 1990;322:1646–51.
Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383.
Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987;70:1727–9.
Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Long-term follow-up of patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 1981;58:1008–11.
Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981;58:122–8.
Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978;18:496–503.
Meryman HT. Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion. Transfusion Med Rev 1989;3:180–93.
Deeg HJ. Transfusions with a tan — Prevention of allosensitization by ultraviolet irradiation. Transfusion 1989;29:450–5.
Brand A, Claas FHJ, Voogt PJ, Waser MNJM, Eernisse JG. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54: 160–6.
Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 1981;9:77–83.
Saarinen UM, Kekomaki R, Siimes MA, Myllyla G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512–7.
Murphy MF, Metcalfe P, Thomas H, et al. Use of leukocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Brit J Haematol 1986;62:529–34.
Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components — A randomized trial. Transfusion 1991;31:588–94.
Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815–20.
Sniecinski I, O’Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA alloimmunization using filtered blood products. Blood 1988;71:1402–7.
Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964–9.
Van Marwijk-Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JWN. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 1991; 77:201–5.
Sintnicolaas K, Sizoo W, Haije WG, et al. Delayed alloimmunization by random single donor platelet transfusions. Lancet 1981;i:750–4.
Gmür J, von Feiten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusion: A prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473–9.
Gmür J, Burger J, Sauter C, Oelz O, Frick PG. Alloimmunization by leukocyte-rich or leukocyte-poor random single donor platelets. In: Rock G (ed). Apheresis. Wiley-Liss, New York, Progress in Clinical and Biological Research 1990;337:45–8.
Sherman L, Menitove J, Kagen LR, et al. Ultraviolet-B irradiation of platelets: A preliminary trial of efficacy. Transfusion 1992;32:402–7.
Menitove JE, Kagen LR, Aster RH, et al. Alloimmunization is decreased in patients receiving UV-B irradiated platelet concentrates and leukocyte-depleted red cells. Blood 1990;16(suppl 1):404d(abstract).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Lee, E.J. (1993). Clinical Strategies for the Prevention of Platelet Alloimmunization. In: Sibinga, C.T.S., Das, P.C., The, T.H. (eds) Immunology and Blood Transfusion. Developments in Hematology and Immunology, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3094-7_23
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3094-7_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6352-1
Online ISBN: 978-1-4615-3094-7
eBook Packages: Springer Book Archive